Evofem Biosciences Announces Last Patient Enrolled for AMPREVENCE, the Phase 2b Sexually Transmitted Infections Trial of Amphora
https://www.ariva.de/news/...ounces-last-patient-enrolled-for-7535054
|
Evofem Biosciences Announces Last Patient Enrolled for AMPREVENCE, the Phase 2b Sexually Transmitted Infections Trial of Amphora
https://www.ariva.de/news/...ounces-last-patient-enrolled-for-7535054
Evofem Biosciences to Report First Quarter 2019 Results and Provide Corporate Update on May 7, 2019
https://evofem.investorroom.com/...ide-Corporate-Update-on-May-7-2019
Balance at December 31, 2018 25,867,248 Shares
Balance at March 31, 2019 | 28,712,174 |
As of March 31, 2019, warrants to purchase approximately 3,587,853 shares of the Company's common stock remain outstanding at a weighted average exercise price of $4.68 per share.
The number of shares of the registrant’s common stock, $0.0001 par value, outstanding as of April 30, 2019 was 35,367,191.
https://www.sec.gov/Archives/edgar/data/1618835/000161883519000084/evfm-331201910xq.htm
To approve the issuance of our common stock pursuant to a private placement financing, including shares of common stock issuable upon the exercise of warrants that will result in a change of control for purposes of Nasdaq Listing Rule 5635(b); and
http://app.quotemedia.com/data/...pe=DEFR14A&dateFiled=2019-05-10
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
8 | 2.032 | Evofem Biosc. - Chancen und Risiken | Trash | Vassago | 12.12.23 16:32 | |
28 | EVFM Start | hulkier | Advamillionär | 24.04.21 23:55 | ||
EVFM | hulkier | 09.09.18 23:10 |